XML 205 R161.htm IDEA: XBRL DOCUMENT v3.22.4
Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Dec. 31, 2022
USD ($)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance € 714 € 605 € 800  
Payments made (136) (258) (122)  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) 5 (4) (35)  
Other movements 0 (14) (10)  
Currency translation differences 40 25 (28)  
New transactions 156 360    
Ending balance 779 714 605  
Non-current liabilities related to business combinations and to non-controlling interests 674 577 387 [1]  
Current liabilities related to business combinations and to non-controlling interests 105 137 218 [1]  
Bayer contingent purchase consideration arising from the acquisition of Genzyme        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance 59 104 156  
Payments made (29) (31) (42)  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (9) (18) 9  
Other movements 0 0 (8)  
Currency translation differences 5 4 (11)  
New transactions 0 0    
Ending balance 26 59 104  
MSD contingent consideration (European vaccines business)        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance 269 312 385  
Payments made (79) (75) (78)  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) 14 26 9  
Other movements 0 0 0  
Currency translation differences 0 6 (4)  
New transactions 0 0    
Ending balance 204 269 312  
Shire contingent consideration arising from the acquisition of Translate Bio        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance 354 0 0  
Payments made 0 0 0  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) 2 19 0  
Other movements 0 0 0  
Currency translation differences 24 12 0  
New transactions 0 323    
Ending balance 380 354 0  
Amunix        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance 0 0 0  
Payments made 0 0 0  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (2) 0 0  
Other movements 0 0 0  
Currency translation differences 11 0 0  
New transactions 156 0    
Ending balance 165 0 0  
Other        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Beginning balance 32 189 259  
Payments made (28) (152) (2)  
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) 0 (31) (53)  
Other movements 0 (14) (2)  
Currency translation differences 0 3 (13)  
New transactions 0 37    
Ending balance € 4 € 32 € 189  
Translate Bio        
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]        
Contingent consideration liabilities | $       $ 382
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.